||Anti-thrombotic for chronic prevention of cardiovascular disease and cancer chemoprevention.
||ATB-340 is a hydrogen sulfide-releasing derivative of low-dose aspirin. Low-dose aspirin is a widely prescribed anti-thrombotic for the maintenance of cardiovascular health.
|TARGET SEGMENT(S) AND MARKETPLACE
||Low-dose aspirin is becoming increasingly regarded as a panacea for cardiovascular disease prevention, and emerging data now suggest it decreases the risk of multiple cancers. However, aspirin, like other NSAIDs, can cause stomach ulcers and serious gastrointestinal bleeding in an appreciable portion of the population.
|WEAKNESS OF PROTON PUMP INHIBITORS (“PPIs”)
||Several combination therapies have been launched recently to address the GI safety issue by combining low-dose aspirin with a proton pump inhibitor (“PPI”). However, although PPIs reduce the risk of upper GI bleeding, no effective therapy to lessen the risk for lower GI bleeding in aspirin users. In fact, recent data has now shown that the use of PPIs increases the risk of lower GI damage significantly (Gastroenterology, 2011). Lower GI toxicity of aspirin is now known to be more insidious than upper GI damage, leading to higher mortality and longer hospital stays (Annals of Internal Medicine, 2010).
||ATB-340 delivers the cardiovascular disease prevention associated with aspirin but without the serious risk of gastrointestinal bleeding. Pre-clinical studies have demonstrated that ATB-340 caused negligible GI damage compared to low-dose aspirin.
||IND-enabling pre-clinical studies for ATB-340 are expected to commence in 2020.